Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,585.60
(
-0.57%
)
Dow Jones
46,021.43
(
0.00%
)
Brent Oil
104.50
(
0.06%
)
Bitcoin
70,601.42
(
1.01%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: randychub post# 43111

Thursday, 03/15/2007 4:38:03 AM

Thursday, March 15, 2007 4:38:03 AM

Post# of 257262
>LEVP – From the rodman webcast - No one else is trying for approval for that market. <

Understood, but I do not see why the C1 inhibitor from LEVP is better suited to prophylactic use than the C1 inhibitor from Pharming.

If both LEVP and Pharming get FDA approval for treatment of acute HAE and if LEVP’s trial for prophylactic use (now in progress) is successful, it would seem that Pharming ought to be able to reproduce LEVP’s prophylactic results and split that segment of the HAE market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now